Drugs / Peg-IFNa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07135349 | Sep 2025 → Jun 2026 overdue | chronic hepatitis B virus infection | Shanghai Argo Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg-IFNa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07135349 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated Interferon Alfa” NCT07135349 ↗ |